"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...
The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...
Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
Antidepressants known as selective serotonin reuptake inhibitors, or SSRIs have been the first line of treatment for mood disorders and anxiety for the last three decades. These medicines mainly ...